Portal de investigação
Comparison of rhinitis treatments using MASK-air® data and considering the minimal important difference
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- Schunemann, HJ
- Anto, JM
- Klimek, L
- Czarlewski, W
- Mullol, J
- Pfaar, O
- Bedbrook, A
- Brussino, L
- Kvedariene, V
- Larenas Linnemann, D
- Okamoto, Y
- Ventura, MT
- Agache, I
- Ansotegui, IJ
- Bergmann, KC
- Bosnic Anticevich, S
- Brozek, J
- Canonica, GW
- Cardona, V
- Carreiro Martins, P
- Casale, T
- Cecchi, L
- Chivato, T
- Chu, DK
- Cingi, C
- Costa, E.
- Cruz, AA
- Del Giacco, S
- Devillier, P
- Eklund, P
- Fokkens, WJ
- Gemicioglu, B
- Haahtela, T
- Ivancevich, JC
- Ispayeva, Z
- Jutel, M
- Kuna, P
- Kaidashev, I
- Khaitov, M
- Kraxner, H
- Laune, D
- Lipworth, B
- Louis, R
- Makris, M
- Monti, R
- Morais Almeida, M
- Mösges, R
- Niedoszytko, M
- Papadopoulos, NG
- Patella, V
- Pham Thi, N
- Regateiro, FS
- Reitsma, S
- Rouadi, PW
- Samolinski, B
- Sheikh, A
- Sova, M
- Todo Bom, A
- Taborda Barata, L
- Toppila Salmi, S
- Sastre, J
- Tsiligianni, I
- Valiulis, A
- Vandenplas, O
- Wallace, D
- Waserman, S
- Yorgancioglu, A
- Zidarn, M
- Zuberbier, T
- Bousquet, J
Unidades de investigação
Abstract
Background Different treatments exist for allergic rhinitis (AR), including pharmacotherapy and allergen immunotherapy (AIT), but they have not been compared using direct patient data (i.e., "real-world data"). We aimed to compare AR pharmacological treatments on (i) daily symptoms, (ii) frequency of use in co-medication, (iii) visual analogue scales (VASs) on allergy symptom control considering the minimal important difference (MID) and (iv) the effect of AIT. Methods We assessed the MASK-air (R) app data (May 2015-December 2020) by users self-reporting AR (16-90 years). We compared eight AR medication schemes on reported VAS of allergy symptoms, clustering data by the patient and controlling for confounding factors. We compared (i) allergy symptoms between patients with and without AIT and (ii) different drug classes used in co-medication. Results We analysed 269,837 days from 10,860 users. Most days (52.7%) involved medication use. Median VAS levels were significantly higher in co-medication than in monotherapy (including the fixed combination azelastine-fluticasone) schemes. In adjusted models, azelastine-fluticasone was associated with lower average VAS global allergy symptoms than all other medication schemes, while the contrary was observed for oral corticosteroids. AIT was associated with a decrease in allergy symptoms in some medication schemes. A difference larger than the MID compared to no treatment was observed for oral steroids. Azelastine-fluticasone was the drug class with the lowest chance of being used in co-medication (adjusted OR = 0.75; 95% CI = 0.71-0.80). Conclusion Median VAS levels were higher in co-medication than in monotherapy. Patients with more severe symptoms report a higher treatment, which is currently not reflected in guidelines.
© 2022 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Dados da publicação
- ISSN/ISSNe:
- 0105-4538, 1398-9995
- Tipo:
- Article
- Páginas:
- 3002-3014
- DOI:
- 10.1111/all.15371
- Link para outro recurso:
- www.scopus.com
ALLERGY Wiley-Blackwell Publishing Ltd
Citações Recebidas na Web of Science: 8
Citações Recebidas na Scopus: 17
Documentos
- Não há documentos
Filiações
Keywords
- allergen immunotherapy; allergic rhinitis; co-medication; multivariable mixed-effects model; real-world data
Campos de estudo
Proyectos asociados
Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal (EPI-ASTHMA) - NCT05169619
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (EPI-ASTHMA) . AstraZeneca . 2021
Effect of a Mobile App on Improving Asthma Control in Adolescents and Adults With Persistent Asthma: A Pilot Randomized Multicentre, Superiority Clinical Trial (mINSPIRERS) - NCT05129527
Investigador Principal: João de Almeida Lopes da Fonseca
Ensaio Clínico Académico (mINSPIRERS) . 2021
Utilização em estudos observacionais do Registo de Asma Grave Portugal.
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Observacional Académico (RAG) . 2020
Clinical Research Collaboration Severe Heterogenous Asthma Research collaboration, Patient-centered (CRC SHARP).
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (SHARP) . European Respiratory Society . 2021
Seroprevalence of SARS-CoV-2 and assessment of epidemiologic determinants in Portuguese municipal workers
Investigador Principal: Bernardo Manuel De Sousa Pinto
Estudo Clínico Académico (SARS-CoV-2) . 2021
Use of secondary data, health technology assessment methods and economic modelling applied to penicillin allergy
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Using different data sources for the identification of asthma patients and those at high risk of adverse outcomes
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Phenotypes of Chronic Diseases of the Airways: Towards Multidimensional Data -Driven Profiling
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Citar a publicação
Sousa B,Schunemann HJ,Sá A,Vieira R,Amaral R,Anto JM,Klimek L,Czarlewski W,Mullol J,Pfaar O,Bedbrook A,Brussino L,Kvedariene V,Larenas D,Okamoto Y,Ventura MT,Agache I,Ansotegui IJ,Bergmann KC,Bosnic S,Brozek J,Canonica GW,Cardona V,Carreiro P,Casale T,Cecchi L,Chivato T,Chu DK,Cingi C,Costa E,Cruz AA,Del Giacco S,Devillier P,Eklund P,Fokkens WJ,Gemicioglu B,Haahtela T,Ivancevich JC,Ispayeva Z,Jutel M,Kuna P,Kaidashev I,Khaitov M,Kraxner H,Laune D,Lipworth B,Louis R,Makris M,Monti R,Morais M,Mösges R,Niedoszytko M,Papadopoulos NG,Patella V,Pham N,Regateiro FS,Reitsma S,Rouadi PW,Samolinski B,Sheikh A,Sova M,Todo A,Taborda L,Toppila S,Sastre J,Tsiligianni I,Valiulis A,Vandenplas O,Wallace D,Waserman S,Yorgancioglu A,Zidarn M,Zuberbier T,Fonseca J,Bousquet J. Comparison of rhinitis treatments using MASK-air® data and considering the minimal important difference. Allergy. 2022. 77. (10):p. 3002-3014. IF:12,400. (1).
